Browsing by Author "Erdem, Ecem Efendi"

Filter results by typing the first few letters
Now showing 1 - 3 of 3
  • No Thumbnail Available
    Publication
    Investigation of VHL gene associated with miR-223 in clear cell renal cell carcinoma
    (Springer, 2021-11-26) Ünal, Ufuk; Çeçener, Gülşah; Ünlü, Havva Tezcan; Vuruşkan, Berna Aytaç; Erdem, Ecem Efendi; Egeli, Ünal; Nazlıoğlu, Hülya Öztürk; Kaygısız, Onur; Tunca, Berrin; Vuruşkan, Hakan; Ünal, Ufuk; ÇEÇENER, GÜLŞAH; Ünlü, Havva Tezcan; AYTAÇ VURUŞKAN, BERNA; Erdem, Ecem Efendi; EGELİ, ÜNAL; ÖZTÜRK NAZLIOĞLU, HÜLYA; KAYGISIZ, ONUR; TUNCA, BERRİN; VURUŞKAN, HAKAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Biyoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Patoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Üroloji Anabilim Dalı.; 0000-0003-4913-3616; 0000-0002-3820-424X; 0000-0002-0910-4258; 0000-0001-7904-883X; 0000-0002-9790-7295; 0000-0002-1619-6680; AAH-1420-2021; L-9439-2019; GYU-0252-2022; ABC-1357-2020; AAP-9988-2020; GYU-0252-2022; EEJ-1452-2022; ESY-2704-2022; FLN-9596-2022; ABI-6078-2020; EFH-9523-2022
    Background Clear cell type renal cell carcinoma (ccRCC) is the most common renal cell carcinoma (RCC). In this study, we examined the expressions of VHL and miR-223 in ccRCC patients' tissues to investigate the possible role in the development of ccRCC.Methods and results This study collected five expression profiles (GSE36139, GSE3, GSE73731, GSE40435, and GSE26032) from Gene Omnibus Data. Expressions of VHL and miR-223 in paraffinized tumor and normal tissues of 100 Turkish patients' ccRCC tissues were determined by bioinformatic data mining and real-time quantitative polymerase chain reaction (qRT-PCR). The VHL gene was subjected to mutational analysis by DNA sequencing, and pVHL was analyzed using western blotting. Our study's t-test and Pearson correlation analysis showed that VHL gene expression in tumoral tissues with a - 0.39-fold decrease was not significantly lower than normal tissues (p = 0.441), and a 0.97-fold increase miR-223 (p = 0.045) was determined by real-time PCR. Also, as a result of DNA sequence analysis performed in the VHL gene, it was found that 26% of the patients have mutations. The mutations for (VHL):c.60C>A (p.Val20=) and (VHL):c.467delA (p.Tyr156Leu) was detected for the first time in Turkish patients.Conclusions The present study demonstrated that the differences in the expression levels of miR-223 have the potential to be biomarkers to determine the poor prognosis in ccRCC.
  • Thumbnail Image
    Item
    Pediatrik vakalarda philadelphia benzeri akut lenfoblastik lösemi
    (Bursa Uludağ Üniversitesi, 2020-12-11) Erdem, Ecem Efendi; Cecener, Gülşah; Tezcan, Havva; Evim, Melike Sezgin; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Biyoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Sağlığı ve Hastalıkları Anabilim Dalı/Çocuk Hematoloji ve Onkolojisi Bilim Dalı.; 0000-0001-9003-8755; 0000-0002-3820-424X; 0000-0002-0910-4258; 0000-0002-4792-269X
    Lösemi, hematopoietik hücrelerin malign transformasyonu sonucu gelişen, heterojen neoplastik hastalıklar grubudur. Philadelphia (Ph) benzeri akut lenfoblastik lösemi (ALL), yüksek risk sınıflamasında yer alan ve kötü prognoz gösteren B- hücreli akut lenfoblastik löseminin (B-ALL) alt grubudur. Gen ekspresyon profili olarak Ph pozitif ALL’ye benzemektedir, ancak bu alt tipte BCR ABL1 füzyonu mevcut değildir. Hastalık genetik olarak heterojendir. Ayrıca, etnik kökenleri farklı olan Ph benzeri ALL vakalarının genetik değişimleri de farklılık göstermektedir. Ph benzeri ALL vakalarının B-ALL’li hastalar arasından ayırt edilerek sınıflandırılabilmesi etkin tedavi almaları için önemlidir. Son yıllarda, Ph benzeri ALL alt grubuna ait vakaların tanımlanması için, B-ALL vakalarında genetik ve klinik bulgular değerlendirilmesinin yanı sıra, gen ifade farklılıklarının analiz edildiği panellerin tasarlanması gündemdedir.
  • No Thumbnail Available
    Item
    Philadelphia-like acute lymphoblastic leukemia in pediatric cases
    (Galenos Yayıncılık, 2021-04) Erdem, Ecem Efendi; Çeçener, Gülşah; Ünlü, Havva Tezcan; Evim, Melike Sezgin; Bursa Uludağ Üniversitesi/Tıp Fakültesi/ Tıbbi biyoloji Anabilim Dalı; Bursa Uludağ Üniversitesi/Tıp Fakültesi/ Çocuk Sağlığı Ve Hastalıkları Anabilim Dalı ve Onkoloji Bilim Dalı; 0000-0002-0910-4258; GYU-0252-2022; ESY-2704-2022; AAP-9988-2020; AAH-1452-2021; 57223043925; 6508156530; 57223050102; 36337796600
    Leukemia is a heterogeneous group of neoplastic diseases that develop as a result of the malignant transformation of hematopoietic cells. Philadelphia (Ph)-like acute lymphoblastic leukemia (ALL) is a subgroup of B-cell acute lymphoblastic leukemia (B-ALL), which is included in the high-risk classification and has a poor prognosis. It is similar to Ph-positive ALL in gene expression profile, but this subtype does not have BCR-ABL1 fusion. The disease is genetically heterogeneous. In addition, the genetic changes of Ph-like ALL cases with different ethnic origins also differ. It is important to distinguish and classify Ph-like ALL cases from patients with B-ALL for effective treatment. In recent years, it is on the agenda to design panels in which gene expression differences are analyzed in addition to evaluating genetic and clinical findings in B-ALL cases to identify cases belonging to the Ph-like ALL subgroup.